Escudero Sánchez G*, Redondo Guijo A, Férnandez Galán MA, González Hurtado JA, López López R and Pardal De La Mano E
Department of Internal Medicine, Hospital Virgen Del Puerto, Plasencia, 10003 Cáceres, SpainFulltext PDF
Plasmablastic Lymphoma (PBL) is an uncommon and aggressive subtype of diffuse large B-cell lymphoma, diagnosed commonly in middle-aged male patients, and historically associated with HIV-positive patients, involving the oral cavity. It has recently been described in HIV-negative patients affecting other levels, such as the pleura, pericardium, etc. This entity is characterized by
having positive CD38 and CD138 receptors, characteristic of plasma cell disease, negative CD20 receptors and high proliferative index (high Ki67). An early diagnosis and initiation of treatment is important, since it significantly improves the bad prognosis. Initial treatment recommended is conventional chemotherapy (CHOP, cyclophosphamide, Adriamycin, vincristine and prednisone)
or more intensive chemotherapy (EPOCH, etoposide plus CHOP). New approaches to this lymphomas includes proteasome inhibitors (bortezomib) adding to conventional chemotherapy. We describe a clinical case of Plasmablastic lymphoma and review the literature.
Escudero Sánchez G, Redondo Guijo A, Férnandez Galán MA, González Hurtado JA, López López R, Pardal De La Mano E. Plasmablastic Lymphoma: Case and Review of the Literature. Clin Oncol. 2021;6:1862..